208 related articles for article (PubMed ID: 12649097)
1. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study.
Pectasides D; Pectasides M; Farmakis D; Bountouroglou N; Nikolaou M; Koumpou M; Mylonakis N; Kosmas C
Ann Oncol; 2003 Apr; 14(4):537-42. PubMed ID: 12649097
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study.
Pectasides D; Pectasides M; Farmakis D; Gaglia A; Koumarianou A; Nikolaou M; Koumpou M; Kountourakis P; Papaxoinis G; Mitrou P; Economopoulos T; Raptis SA
Gynecol Oncol; 2004 Oct; 95(1):165-72. PubMed ID: 15385127
[TBL] [Abstract][Full Text] [Related]
3. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes.
Kalbakis K; Kouroussis C; Kakolyris S; Mavroudis D; Souglakos J; Agelaki S; Vamvakas L; Christodoulakis M; Stylianou K; Georgoulias V
Br J Cancer; 2001 Sep; 85(6):798-802. PubMed ID: 11556827
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients.
Sun S; Wang LP; Zhang J; Yang XY; Zhang QL; Jia Z; Hu XC; Wang BY
Med Oncol; 2012 Jun; 29(2):418-24. PubMed ID: 21298496
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients.
Zelek L; Cottu P; Tubiana-Hulin M; Vannetzel JM; Chollet P; Misset JL; Chouaki N; Marty M; Gamelin E; Culine S; Dieras V; Mackenzie S; Spielmann M
J Clin Oncol; 2002 May; 20(10):2551-8. PubMed ID: 12011135
[TBL] [Abstract][Full Text] [Related]
6. Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study.
Hegewisch-Becker S; Gruber Y; Corovic A; Pichlmeier U; Atanackovic D; Nierhaus A; Hossfeld DK
Ann Oncol; 2002 Aug; 13(8):1197-204. PubMed ID: 12181242
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.
de Gramont A; Vignoud J; Tournigand C; Louvet C; André T; Varette C; Raymond E; Moreau S; Le Bail N; Krulik M
Eur J Cancer; 1997 Feb; 33(2):214-9. PubMed ID: 9135491
[TBL] [Abstract][Full Text] [Related]
8. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
Masi G; Allegrini G; Cupini S; Marcucci L; Cerri E; Brunetti I; Fontana E; Ricci S; Andreuccetti M; Falcone A
Ann Oncol; 2004 Dec; 15(12):1766-72. PubMed ID: 15550581
[TBL] [Abstract][Full Text] [Related]
9. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
Souglakos J; Mavroudis D; Kakolyris S; Kourousis Ch; Vardakis N; Androulakis N; Agelaki S; Kalbakis K; Tsetis D; Athanasiadis N; Samonis G; Georgoulias V
J Clin Oncol; 2002 Jun; 20(11):2651-7. PubMed ID: 12039926
[TBL] [Abstract][Full Text] [Related]
10. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
[TBL] [Abstract][Full Text] [Related]
11. Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer.
Klaassen U; Wilke H; Weyhofen R; Harstrick A; Eberhardt W; Müller C; Korn M; Hanske M; Diergarten K; Seeber S
Anticancer Drugs; 1998 Mar; 9(3):203-7. PubMed ID: 9625430
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer.
Delozier T; Guastalla JP; Yovine A; Levy C; Chollet P; Mousseau M; Delva R; Coeffic D; Vannetzel JM; Zazzi ES; Brienza S; Cvitkovic E
Anticancer Drugs; 2006 Oct; 17(9):1067-73. PubMed ID: 17001180
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: a phase II study.
Yang TS; Chen JS; Tang R; Chiang JM; Hsieh PS; Yeh CY; Changchien CR
Chemotherapy; 2003 Jul; 49(4):194-9. PubMed ID: 12886055
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
Martinez J; Martin C; Chacon M; Korbenfeld E; Bella S; Senna S; Richardet E; Coppola F; Bas C; Hidalgo J; Escobar E; Reale M; Smilovich AM; Wasserman E
Am J Clin Oncol; 2006 Feb; 29(1):45-51. PubMed ID: 16462502
[TBL] [Abstract][Full Text] [Related]
17. Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study.
Rougier P; Lepille D; Bennouna J; Marre A; Ducreux M; Mignot L; Hua A; Méry-Mignard D
Ann Oncol; 2002 Oct; 13(10):1558-67. PubMed ID: 12377643
[TBL] [Abstract][Full Text] [Related]
18. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
Comella P; Casaretti R; De Rosa V; Avallone A; Izzo F; Fiore F; Lapenta L; Comella G
Ann Oncol; 2002 Dec; 13(12):1874-81. PubMed ID: 12453855
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer.
Chao Y; Yeh KH; Chang CJ; Chen LT; Chao TY; Wu MF; Chang CS; Chang JY; Chung CY; Kao WY; Hsieh RK; Cheng AL
Br J Cancer; 2004 Aug; 91(3):453-8. PubMed ID: 15226770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]